A bottle of melatonin can seem like a simple answer to a long night. It is familiar, widely available and associated with sleep. During or after breast cancer treatment, I would still ask what problem we are trying to solve: difficulty falling asleep, repeated waking, hot flashes, pain or a disrupted sleep schedule.
Evidence at a glance
Studied use: oral melatonin for sleep symptoms during treatment or survivorship. Signal: some small trials show better self-reported sleep. Certainty: limited and inconsistent across settings. Not established: that better sleep means less recurrence or longer survival.
The survivor study
A 2014 placebo-controlled trial randomized 95 postmenopausal women with a history of stage 0–III breast cancer to oral melatonin 3 mg daily or placebo for four months. All had completed active treatment, including hormonal therapy.
Average Pittsburgh Sleep Quality Index scores improved by 1.9 points with melatonin and 0.1 with placebo. The roughly 1.8-point separation was statistically significant, but does not tell us how many people achieved a personally worthwhile improvement. Only about half reported poor sleep at baseline.
Depression and hot flashes did not improve significantly. Eighty-six women completed the study, and complete total sleep-score data were available for fewer. These findings support a possible sleep benefit in this selected survivor population, not a general promise during endocrine therapy.
A newer trial needs a careful reading
A September 2026 report studied 40 women with stage I–III breast cancer receiving adjuvant chemotherapy. The research regimen was 6 mg daily for six months. Its abstract reports improvements in some sleep measures, with results differing across chemotherapy phases.
However, that abstract also describes an anxiety result as statistically significant while reporting P=.077. That inconsistency needs clarification. With a small sample and limited detail available in the abstract, I would treat it as a preliminary signal rather than a reason to change routine care.
How the broader evidence fits
The April 30, 2025 Cochrane review included 30 studies involving 5,093 people with cancer. Its search ended September 10, 2024, so it does not resolve the newer report. For sleep and quality of life at three months during cancer treatment, the evidence was very uncertain. The total participant count should not be mistaken for thousands of people contributing reliable sleep data.
The 2023 ESMO guideline offers a narrower clinical role: consider melatonin when circadian rhythm disruption appears important and suitable nonmedication options are limited. It does not establish one cancer-specific dose. CBT-I remains the standard of care for survivor insomnia, discussed in our earlier sleep review.
The label and the next morning matter
The trial doses above are research descriptions, not personal prescribing. Immediate-release, prolonged-release and mixed-ingredient products should not be assumed equivalent. NCCIH notes daytime sleepiness, headache, dizziness and nausea, uncertain long-term safety, and variability in supplement contents.
Medication review is especially important with blood thinners or epilepsy. Ask the oncology pharmacist to review the exact product alongside cancer treatment and other sedating medicines. More milligrams should not become the automatic response to another bad night.
Questions for the care team
- What is driving my sleep problem, and is my sleep timing disrupted?
- Would CBT-I or a shorter behavioral program fit my treatment schedule?
- If we consider melatonin, which formulation, timing and reassessment plan make sense?
- What improvement in sleep and daytime function would justify continuing?
Evidence checked October 7, 2026. Educational review; individual treatment decisions belong with your care team. Explore the Missing Script article library and the podcast—coming soon.
